Liver News and Research

RSS

Repros Therapeutics receives further clarification on the Full Clinical Hold status of Proellex

Repros Therapeutics today announced that the Company has received further clarification from the Food and Drug Administration (FDA) on the Full Clinical Hold status of Proellex.

29 Sep 2009

Januvia in combination with metformin or taken alone lowers blood sugar

A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

29 Sep 2009

Underinsured struggle to keep up with bills; uninsured seek clinic care or play the odds

The underinsured are continuing their struggle to keep up with piling medical bills, and are seeking care at federally funded clinics in greater-than-ever numbers, but some choose to remain uninsured.

29 Sep 2009

Child health experts to gather in Italy for Excellence in Paediatrics conference

Obesity, the flu pandemic and diabetes are just three of the hot topics that will be explored when top child health experts gather in Italy for Excellence in Paediatrics from 3 to 6 December 2009.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

NIH grants $5 million to Pittsburgh researchers

Regenerative medicine researchers at the University of Pittsburgh received two grants totaling more than $5 million from the National Institutes of Health (NIH) to explore new methods for cultivating replacement cells from existing tissues and organs.

26 Sep 2009

Non-AIDS-defining malignancies more prevalent among HIV-infected patients than non-HIV patients

Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.

25 Sep 2009

The Australian Institute of Policy and Science awards Dr Jake Baum for malaria research

Research aimed at developing drugs that stop malaria parasites from spreading throughout the body has seen Dr Jake Baum, from the Walter and Eliza Hall Institute, named a Young Tall Poppy by the Australian Institute of Policy and Science.

25 Sep 2009

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

Vertex Pharmaceuticals Incorporated today announced that sustained virologic response (SVR) data from Study C208, which evaluated twice-daily dosing of Vertex’s investigational hepatitis C virus (HCV) protease inhibitor telaprevir, will be presented in an oral presidential plenary session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place Oct. 30 – Nov. 3, 2009 in Boston.

25 Sep 2009

Research to improve the targeting of chemotherapeutic drugs to specific cells

Kenneth Longmuir, associate professor of physiology & biophysics, and Richard Robertson, professor of anatomy & neurobiology, used liposomes, small spheres (less-than 100 nanometer in diameter) of naturally-occurring lipid molecules, as "packages" for the cancer chemotherapeutic agent doxorubicin, and a small peptide molecule to "address" the package to the targeted tissue.

25 Sep 2009

Research to develop small-molecule drug that blocks excess iron absorption

Excess iron in the body, if left unchecked, can form toxic deposits in major organs leading to serious conditions including heart failure, diabetes, liver cirrhosis, arthritis, and even infertility. Iron overload can be a consequence of a genetically mutated gene known as hereditary hemochromatosis, or a consequence of red blood cell transfusions, required as life saving treatments, for patients with diseases such as thalassemia.

25 Sep 2009

Current stem cell applications to be discussed at NJIT

Stem cell researcher Treena Livingston Arinzeh will discuss current stem cell applications at NJIT, including the regeneration of bone and cartilage for bone fracture and osteoarthritis treatments, spinal cord repair, and liver regeneration at NJIT's first Research Caf.

25 Sep 2009

Huachansu may slow cancer progression

Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.

25 Sep 2009

Tooth cell banking for the treatment of future diseases

Pioneered by BioEDEN, tooth cell banking is a safe, natural and wholly non-invasive method of collecting and preserving precious stem cells which could hold the key to children's health.

25 Sep 2009

PNNL Department of Energy researcher earns prestigious NIH Director's New Innovator Award

An analytical chemist at the Department of Energy's Pacific Northwest National Laboratory has been recognized with a National Institutes of Health Director's New Innovator Award. The award will support Wei-Jun Qian's drive to make new research and clinical diagnostic tools that are dramatically more sensitive, reliable and faster than current technologies.

24 Sep 2009

Genetic variation helps identify hepatitis C infected people, according to a study

Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments.

24 Sep 2009

Researchers visualize vasculature within native liver cyst walls of human ADPKD patients

As part of an effort to develop effective medical therapies that block the progression of liver cyst growth in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), researchers at the University of Colorado Anschutz Medical Center have found that the liver cyst walls develop and maintain a vasculature as they grow out from the body of the liver and that factors released by epithelial cells that line the liver cyst wall lumen can drive the proliferation and development of vascular endothelial cells.

24 Sep 2009

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.

23 Sep 2009

New drug test promises to yield quick and effective response for cancer therapy

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

23 Sep 2009

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

One of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

23 Sep 2009

Liver News and Research

Repros Therapeutics receives further clarification on the Full Clinical Hold status of Proellex

Januvia in combination with metformin or taken alone lowers blood sugar

Underinsured struggle to keep up with bills; uninsured seek clinic care or play the odds

Child health experts to gather in Italy for Excellence in Paediatrics conference

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

NIH grants $5 million to Pittsburgh researchers

Non-AIDS-defining malignancies more prevalent among HIV-infected patients than non-HIV patients

The Australian Institute of Policy and Science awards Dr Jake Baum for malaria research

Vertex Pharmaceuticals to present SVR data at the 60th Annual Meeting of the American Association

Research to improve the targeting of chemotherapeutic drugs to specific cells

Research to develop small-molecule drug that blocks excess iron absorption

Current stem cell applications to be discussed at NJIT

Huachansu may slow cancer progression

Tooth cell banking for the treatment of future diseases

PNNL Department of Energy researcher earns prestigious NIH Director's New Innovator Award

Genetic variation helps identify hepatitis C infected people, according to a study

Researchers visualize vasculature within native liver cyst walls of human ADPKD patients

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

New drug test promises to yield quick and effective response for cancer therapy

Sorafenib with chemotherapy for breast cancer patients had a 74% percent improvement in the time they lived

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News